FBIO - Fortress Biotech, Inc.
| Previous Close | 2.7900 |
| Open | 2.8500 |
| Bid | 2.9000 x 1300 |
| Ask | 3.0300 x 900 |
| Day's Range | 2.8400 - 3.1100 |
| 52 Week Range | 1.2000 - 3.1100 |
| Volume | 995,643 |
| Avg. Volume | 437,506 |
| Market Cap | 209.509M |
| Beta (5Y Monthly) | 2.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9760 |
| Earnings Date | Aug 11, 2019 - Aug 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.80 |
- GlobeNewswire
Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA
NEW YORK, Feb. 13, 2020 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.
- GlobeNewswire
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering
Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced that it has priced an underwritten public offering of 625,000 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $20 per share, with expected gross proceeds to Fortress of $12.5 million. In addition, Fortress has granted the underwriters a 45-day option to purchase up to 93,750 additional shares at the public offering price, less underwriting discounts and commissions.
- GlobeNewswire
Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020
NEW YORK, Jan. 22, 2020 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.
- Benzinga
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune ...
- Simply Wall St.
Loss-Making Fortress Biotech, Inc. (NASDAQ:FBIO) Expected To Breakeven
Fortress Biotech, Inc.'s (NASDAQ:FBIO): Fortress Biotech, Inc. develops and commercializes pharmaceutical and...
- GlobeNewswire
Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease
NEW YORK, Jan. 16, 2020 -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing.
- GlobeNewswire
Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that feedback from the U.S. Food and Drug Administration (“FDA”) has confirmed the company’s plan to submit cosibelimab for full approval as a treatment for patients with metastatic cutaneous squamous cell carcinoma (“CSCC”) based on efficacy and safety data from the ongoing open-label, multicenter, Phase 1 clinical trial, Study CK-301-101 (NCT03212404). This registration-enabling clinical trial is currently enrolling a cohort of patients with metastatic CSCC, with a target enrollment of approximately 75 to 100 patients and a primary efficacy endpoint of confirmed objective response rate (“ORR”) assessed by independent central review.
- GlobeNewswire
Journey Medical Corporation Recaps 2019 Growth
Journey Medical Corporation today announced an update on its growth and business performance, including preliminary unaudited fourth quarter and full-year 2019 net revenue. “2019 was a banner year for us,” said Claude Maraoui, president and chief executive officer of Journey Medical.
- GlobeNewswire
Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders
NEW YORK, Dec. 23, 2019 -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) today announced that Baergic Bio, Inc. (“Baergic”), a newly formed Fortress partner company, has.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Fortress Biotech Inc (FBIO)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the third quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
- GlobeNewswire
Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol
The NDA for IV tramadol is based on positive results from two pivotal Phase 3 clinical efficacy and safety trials in patients following bunionectomy and abdominoplasty surgeries, as well as an open-label safety study with a total of more than 500 patients who received the IV tramadol 50 mg dosing regimen. In addition, the NDA includes an epidemiology study on abuse of tramadol in the U.S. and in certain European countries where IV tramadol is available. “As a potential alternative that could reduce the use of conventional opioids, IV tramadol may fill a gap between IV acetaminophen/NSAIDs and IV conventional narcotics in the acute pain space,” said Lucy Lu, M.D., Avenue’s President and Chief Executive Officer.
- GlobeNewswire
Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency
MB-107 preceded by low-dose busulfan conditioning continues to be well tolerated and results in development of functional immune system in newly diagnosed infants with XSCID.
- Benzinga
The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...
- GlobeNewswire
Fortress Biotech to Participate in December 2019 Investor Conferences
Benchmark’s 8th Annual Discovery One-on-One Conference: Fortress will host one-on-one meetings on Wednesday, December 4, 2019, at the New York Athletic Club in New York City. 12th Annual LD Micro Main Event Investor Conference: Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a company overview on Tuesday, December 10, 2019, at 2 p.m. PST at the Lux Sunset Bel Air Hotel in Los Angeles. Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates.
- GlobeNewswire
Mustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx Conference
NEW YORK, Dec. 02, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.
- Benzinga
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction ...
- GlobeNewswire
Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock
Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of its previously announced underwritten public offering. Checkpoint is offering 13,400,000 shares of its common stock, par value $0.0001 per share, at a price to the public of $1.27 per share. In connection with the offering, Checkpoint has also granted the underwriters a 45-day option to purchase up to an additional 2,010,000 shares of common stock offered in the public offering, at the same public offering price per share, less underwriting discounts and commissions.
- GlobeNewswire
Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock
Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Checkpoint expects to grant the underwriters a 45‐day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering. All of the shares of common stock are being offered by Checkpoint.
- GlobeNewswire
Fortress Biotech Ranked in Top 10 of Deloitte’s 2019 Technology Fast 500™
Fortress’ 8,463 percent revenue growth based on the increase in net product sales from 2015 to 2018 secured its spot in the ranking. This recognition underscores our rapid revenue growth and validates our unique business model.
- GlobeNewswire
Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, Nov. 12, 2019 -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing.
- GlobeNewswire
Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, Nov. 12, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.
- Simply Wall St.
Do Insiders Own Shares In Fortress Biotech, Inc. (NASDAQ:FBIO)?
Every investor in Fortress Biotech, Inc. (NASDAQ:FBIO) should be aware of the most powerful shareholder groups...
- GlobeNewswire
Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
NEW YORK, Nov. 08, 2019 -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new.
- GlobeNewswire
Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, Nov. 07, 2019 -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immunotherapy and targeted oncology company, today announced financial.
